Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on How Elinzanetant Affects Dabigatran Etexilate in Healthy Volunteers with Vasomotor Symptoms

Registered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on understanding how the study drug elinzanetant (also known by its code name BAY 3427080) affects the way another drug, dabigatran etexilate, moves into, through, and out of the body. The study involves healthy male and female participants. Elinzanetant is being studied for its potential effects on vasomotor symptoms, which are symptoms like hot flashes that can occur due to changes in hormone levels in both women and men.

The purpose of the study is to investigate the effect of a single dose of elinzanetant on the exposure of dabigatran etexilate in the body. Participants will receive a single dose of elinzanetant and then the movement of dabigatran etexilate in their bodies will be monitored. The study will help researchers understand how these two drugs interact when taken together.

During the study, participants will be monitored for any side effects or adverse events that may occur. The study aims to ensure the safety of participants while gathering important information about how these drugs work together. This research is important for developing better treatments for managing symptoms related to hormone changes.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will attend an initial visit. During this visit, a medical evaluation will be conducted to confirm your health status. This includes reviewing your medical history, conducting a physical examination, checking your blood pressure and pulse rate, performing a 12-lead electrocardiogram (ECG), and conducting laboratory tests.

    Your body weight and body mass index (BMI) will be measured to ensure they meet the study requirements. You must weigh at least 50 kg, and your BMI should be between 18.0 and 30.0 kg/m².

  2. Step 2

    Medication administration

    You will receive a single oral dose of the study drug elinzanetant (also known as BAY 3427080). This medication is provided in the form of a soft capsule.

    Following this, you will be given dabigatran etexilate, which is provided as a hard capsule under the name Pradaxa 75 mg. The purpose is to observe how elinzanetant affects the way dabigatran moves through your body.

  3. Step 3

    Monitoring and observation

    After taking the medications, you will be monitored to assess how your body processes the drugs. This involves measuring the maximum concentration (Cmax) and the area under the curve (AUC) of dabigatran in your system.

    You will be observed for any treatment-emergent adverse events (TEAEs), which are any side effects that may occur after taking the medication.

  4. Step 4

    Follow-up

    A follow-up visit will be scheduled to review your health status and any effects experienced during the trial. This ensures your safety and well-being throughout the study.

Who can join the trial?

5 criteria

  • Participant must be between 18 and 65 years old at the time of signing the consent form.
  • Participants should be overtly healthy, meaning they should not have any noticeable health issues. This will be determined by a medical check-up, which includes reviewing medical history, a physical exam, checking blood pressure, pulse rate, a heart test called a 12-lead electrocardiogram (ECG), and laboratory tests.
  • Participants must weigh at least 50 kg (about 110 pounds) and have a body mass index (BMI) between 18.0 and 30.0. BMI is a measure that uses height and weight to estimate body fat.
  • Both males and females can participate.
  • Participants must use birth control methods that comply with local regulations if they are sexually active. This applies to both men and women.

Who cannot join the trial?

10 criteria

  • Participants must not have any serious health conditions that could interfere with the study.
  • Participants should not be taking any medications that might affect the study results.
  • Participants must not have a history of allergic reactions to the study medication.
  • Participants should not be pregnant or breastfeeding.
  • Participants must not have participated in another clinical trial recently.
  • Participants should not have any substance abuse issues.
  • Participants must not have any mental health conditions that could affect their ability to participate.
  • Participants should not have any significant liver or kidney problems.
  • Participants must not have any blood disorders.
  • Participants should not have any heart conditions that could interfere with the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Elinzanetant

    is a medication being studied to see how it affects the way another drug is processed in the body. In this trial, participants receive a single dose of elinzanetant to understand its impact on the levels of another medication in the bloodstream. This helps researchers learn more about how elinzanetant might interact with other drugs.

  • Dabigatran Etexilate

    is a medication that is usually used to prevent blood clots. In this study, it is given to participants to see how its levels in the blood are affected when taken with elinzanetant. By understanding this interaction, researchers can ensure that dabigatran etexilate is used safely and effectively when combined with other medications.

What is already known about the treatment

Elinzanetant – Elinzanetant is administered orally and is currently being studied in clinical trials to understand its effects on the body when taken with another medication, dabigatran etexilate. It is not yet widely used in medicine, as it is still under investigation. The main focus of this study is to see how elinzanetant affects the body's handling of dabigatran etexilate, a medication used to prevent blood clots. Elinzanetant works by influencing hormone-related processes in the body, which may help manage symptoms related to hormone imbalances. It is classified as a medication that targets hormone pathways, specifically for conditions like vasomotor symptoms, which are related to hormone changes in both men and women.

Investigated diseases

Vasomotor Symptoms – Vasomotor symptoms are characterized by episodes of flushing and sweating, often referred to as hot flashes or night sweats. These symptoms are commonly associated with hormonal changes, particularly during menopause in women, but can also occur in men. The episodes can vary in frequency and intensity, often leading to discomfort and disruption of daily activities. The underlying cause is believed to be related to changes in the body's temperature regulation due to fluctuating hormone levels. These symptoms can persist for varying durations, sometimes lasting for several years. They are a common aspect of the natural aging process in both women and men.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2022-500201-41-00Protocol code22081Estimated enrolment20 patientsSponsorBayer AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).